Autonomix Medical Presents New Subgroup Clinical Data From PoC Study At 2026 ASCO GI Demonstrating Durable And Meaningful Pain Relief In Pancreatic Cancer Patients Across All Disease Stages

New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage patients with otherwise limited treatment options

THE WOODLANDS, TX, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced new subgroup clinical data from its PoC study presented at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium demonstrating rapid, durable and meaningful pain relief in pancreatic cancer patients across all disease stages. The analysis expands upon previously reported data from the Company's ongoing clinical evaluation and examines outcomes by pancreatic cancer stage in patients treated for severe pancreatic cancer-related pain.

The post hoc subgroup analysis expands upon previously reported findings from the Company's ongoing Proof-of-Concept 1 (PoC 1) study, evaluating pancreatic cancer patients with severe baseline pain treated using a transvascular RF denervation platform. The analysis stratified outcomes by cancer stage, ranging from Stage 2 through Stage 4¹, and revealed consistent pain reduction regardless of disease severity.